The TMPRSS6 gene encodes matriptase-2¹¹ matriptase-2
A type II transmembrane serine protease expressed primarily in the liver, whose primary role is to cleave hemojuvelin and thereby suppress hepcidin production, the master regulator of hepcidin²² hepcidin
A 25-amino-acid peptide hormone produced by the liver that controls systemic iron homeostasis by degrading ferroportin, the sole iron export channel on gut enterocytes and macrophages. When matriptase-2 functions normally, it suppresses hepcidin, allowing dietary iron to cross from the gut into the bloodstream. When matriptase-2 activity is reduced — whether from coding variants like rs855791 or regulatory variants that modulate gene expression — hepcidin rises and iron absorption falls.

The rs228918 variant sits approximately 2 kilobases upstream of the TMPRSS6 transcription start site, within the gene's 5' regulatory region. Unlike the well-characterized coding variant rs855791 (Ala736Val), rs228918 does not change the matriptase-2 protein itself. Instead, it lies in a region that influences how much matriptase-2 the liver produces. Variants in this region have been examined across multiple ethnic cohorts as part of the broader TMPRSS6 locus.

The Mechanism

As a regulatory variant, rs228918 is thought to influence TMPRSS6 expression levels rather than enzymatic function directly. The upstream region of TMPRSS6 contains binding sites for transcription factors involved in liver iron sensing, including elements responsive to the BMP/SMAD signaling pathway³³ BMP/SMAD signaling pathway
Bone morphogenetic protein / son of mothers against decapentaplegic: a liver-expressed signaling cascade that drives hepcidin gene transcription in response to iron loading. A variant that reduces TMPRSS6 transcription would produce less matriptase-2, leave more hemojuvelin intact on liver cell surfaces, and consequently drive higher hepcidin production — the same downstream consequence as a loss-of-function coding variant, achieved through reduced gene expression.

The C allele (minor allele at rs228918) is associated with the iron-reducing direction. This is consistent with the broader TMPRSS6 locus pattern in GWAS: several upstream and intronic variants near rs228918 (including rs228921, rs228919, and the coding rs4820268) travel together as a haplotype, and the minor allele consistently tags lower iron stores compared to the reference allele.

The Evidence

A systematic review with meta-analyses⁴⁴ systematic review with meta-analyses
Gichohi-Wainaina WN et al. Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators. Genes Nutr, 2015 examined eight TMPRSS6 SNPs — including rs228918 — across 11 Caucasian, 4 Asian, and 1 African-American study cohort. The analysis documented inter-ethnic differences in minor allele frequencies, with rs228918 showing consistent directionality across populations. Effect sizes for this regulatory variant were smaller and less precisely estimated than for rs855791, reflecting its role as a locus-depth signal rather than the primary functional driver.

In a cohort of 686 South African women⁵⁵ cohort of 686 South African women
Gichohi-Wainaina WN et al. Common variants and haplotypes in the TF, TNF-alpha, and TMPRSS6 genes are associated with iron status in a female Black South African population. J Nutr, 2015, the haplotype carrying the protective (T) allele at rs228918 combined with the protective allele at rs228921 was associated with lower odds for elevated soluble transferrin receptor concentrations above 8.3 mg/L (OR 0.79; 95% CI 0.63, 0.98). Elevated soluble transferrin receptor is a sensitive marker of iron deficiency at the tissue level, rising before hemoglobin falls.

A 2016 multi-cohort study⁶⁶ 2016 multi-cohort study
Gichohi-Wainaina WN et al. Associations between common variants in iron-related genes with haematological traits in populations of African ancestry. PLoS One, 2016 in 2,073 individuals across four African ancestry cohorts (Kenya, Tanzania, South Africa, African Americans) confirmed that TMPRSS6 variants contribute to hemoglobin variation even in populations where the primary coding variant rs855791 has lower frequency.

Practical Implications

The practical consequences of rs228918 are directionally identical to those of rs855791 but likely smaller in magnitude. The C allele tags a modest reduction in iron absorption efficiency, mediated through lower TMPRSS6 expression and consequently higher hepcidin. For most people carrying one or two C alleles and eating a balanced diet with adequate iron, this has no clinical consequence.

The effect becomes relevant when iron demand increases: during menstruation, pregnancy, adolescent growth, vegetarian or vegan dietary patterns, or endurance athletics. In these situations, even modest reductions in iron absorption efficiency can contribute to suboptimal iron stores over time. Prioritizing bioavailable iron sources, pairing plant iron with vitamin C, and periodic ferritin monitoring are proportionate responses.

If you also carry the more potent coding variant rs855791 AA genotype, the regulatory effects of rs228918 add to the functional deficit. The combination of reduced TMPRSS6 expression (this variant) and reduced matriptase-2 enzymatic activity (rs855791) compounds the hepcidin-raising effect.

Interactions

rs228918 and rs855791 are both in the TMPRSS6 locus on chromosome 22. They are partially correlated through linkage disequilibrium but are not identical signals — rs228918 captures variation in TMPRSS6 expression while rs855791 captures variation in matriptase-2 enzyme activity. The combined effect of carrying the C allele at rs228918 and the A allele at rs855791 is likely additive within the hepcidin pathway.

rs228918 also has documented haplotype structure with rs228921 (located approximately 196 bp downstream at chr22:37,110,836), and these two upstream variants often travel together. The protective allele combination (T at both loci on the plus strand) is associated with better iron status than the risk haplotype (C at both loci) in population studies.

For people who also carry HFE variants (rs1800562 C282Y or rs1799945 H63D), the directionality matters: TMPRSS6 variants raise hepcidin (reducing absorption) while HFE variants lower it (increasing absorption). These opposing effects require blood-test confirmation of actual iron status rather than relying on genetics alone.

Every time your body encounters a pathogen — a bacterium, virus, or fungus — a molecular alarm system fires inside your immune cells. At the heart of this alarm is NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells)¹¹ NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells)
A family of transcription factors that control the expression of hundreds of immune and inflammatory genes, and NFKB1 encodes its critical p105/p50 subunit. Without adequate NF-κB1 activity, innate and adaptive immunity both falter. The rs230523 variant is a common intronic polymorphism in NFKB1 that was identified in a large-scale genome-wide association study as a modest but highly significant contributor to infection susceptibility.

The Mechanism

NFKB1 encodes two related proteins: the full-length p105 precursor, which acts as an inhibitor of NF-κB in the cytoplasm, and the processed p50 subunit, which dimerizes with p65 (RelA) to form the canonical NF-κB transcriptional activator. When pattern recognition receptors such as Toll-like receptors detect pathogen components, signaling cascades degrade the inhibitor IκB, freeing p50-p65 dimers to translocate into the nucleus and switch on hundreds of target genes — including cytokines (IL-6, TNF-α, IL-1β), chemokines, adhesion molecules, and antimicrobial peptides. rs230523 lies within an intron and does not alter the protein sequence, but intronic variants can influence splicing efficiency, mRNA stability, or regulatory element activity²² splicing efficiency, mRNA stability, or regulatory element activity
Many intronic variants alter binding sites for splicing regulators or transcription factors without changing the coded amino acids. The precise regulatory mechanism for rs230523 has not been characterized at the molecular level.

The clinical importance of the NFKB1 gene itself is well-established. Rare loss-of-function mutations in NFKB1 cause haploinsufficiency³³ loss-of-function mutations in NFKB1 cause haploinsufficiency
Having only one functional copy of the gene, producing approximately half the normal amount of p50 protein and are the most frequent single-gene cause of Common Variable Immunodeficiency (CVID)⁴⁴ Common Variable Immunodeficiency (CVID)
The most prevalent symptomatic antibody deficiency, characterized by recurrent bacterial infections and hypogammaglobulinemia, accounting for 4–5% of CVID cases in European cohorts. The rs230523 GWAS signal likely reflects a common, milder perturbation of NFKB1 regulation that sits on a continuum with these rarer, more severe loss-of-function variants.

The Evidence

Tian et al. (2017)⁵⁵ Tian et al. (2017)
Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. Nature Communications. conducted 23 genome-wide association studies for common infections in over 200,000 individuals of European ancestry through 23andMe. rs230523, mapping to NFKB1 on chromosome 4, reached genome-wide significance for overall infection susceptibility (OR≈1.07, P=4.5×10⁻¹⁴). While the per-allele odds ratio of 1.07 is modest, the extreme statistical significance across a very large, well-powered sample confirms this is a genuine genetic association rather than a false positive. The study captured self-reported lifetime history of common infections across 23 conditions including respiratory infections, urinary tract infections, and viral illnesses.

Chong et al. (2024)⁶⁶ Chong et al. (2024)
A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy. American Journal of Human Genetics. used serology-based GWAS in 9,611 UK Biobank participants — measuring actual antibody titers against 45 pathogen antigens — with validation in 487,297 participants. The NFKB1 locus emerged as the top signal influencing antibody responses to herpes, retro-, and polyomaviruses. The functional causal variant at this locus was proposed to be rs28362491, a 4-base-pair insertion- deletion in the NFKB1 5' regulatory region that affects gene expression; rs230523 likely tags the same functional signal through linkage disequilibrium.

On the rarer-variant side, Fliegauf et al. (2015)⁷⁷ Fliegauf et al. (2015) demonstrated that haploinsufficiency causing ~50% reduction in p50 protein leads to CVID with recurrent bacterial infections, while Li et al. (2021)⁸⁸ Li et al. (2021) systematically showed that among 90 variants found in CVID patients, 59 were biochemically deleterious, compared to only 2 of 260 population variants — establishing a strong genotype-phenotype relationship across the NFKB1 allelic spectrum.

Practical Actions

The OR of 1.07 per C allele translates to a small absolute risk increment — roughly 7% more likely to report having had a common infection, not 7 percentage points more likely overall. For CC homozygotes (two risk alleles), this compounds to approximately 14% increased relative likelihood. The practical implication is a modest tilt in innate immune responsiveness, most relevant when the immune system is already stressed: during novel pathogen exposure, periods of intense physical stress, or with suboptimal micronutrient status.

NF-κB1 activity depends on adequate zinc, vitamin D, and selenium — micronutrients that act as co-regulators of NF-κB pathway components. Ensuring optimal levels of these supports the immune gene expression network that NF-κB1 coordinates.

Interactions

The most important functional variant at this locus is likely rs28362491 (the -94ins/delATTG variant in the NFKB1 5' UTR), which has been independently associated with infection susceptibility and altered NFKB1 expression. rs230523 and rs28362491 are in the same chromosomal region and may tag the same causal signal; if both are measured, their combined interpretation should be treated with caution to avoid double-counting the same underlying effect.

TLR signaling variants (such as rs4986790 in TLR4 and rs5743708 in TLR1) act upstream of NF-κB activation. When both a TLR signaling variant and an NFKB1 variant are present, the downstream NF-κB response to pathogen recognition may be doubly attenuated, compounding infection susceptibility through both receptor-level and transcription-factor-level mechanisms.

The lymphotoxin-beta receptor (LTBR, also known as TNFRSF3) is a cell-surface receptor of the tumor necrosis factor receptor superfamily¹¹ tumor necrosis factor receptor superfamily
TNFRSF members are structurally related receptors that bind TNF-family cytokines and regulate inflammation, cell survival, and lymphoid organ development that governs how your immune cells build and maintain organized lymphoid architecture. LTBR sits at the hub of a signaling network that tells stromal cells to differentiate into the specialized vasculature and reticular scaffolds that make lymph nodes, Peyer's patches, and other secondary lymphoid organs function. Without proper LTBR signaling, these structures fail to form — and without well-organized lymphoid tissue, the immune system cannot mount ordered, antigen-specific responses.

rs2364480 is a synonymous coding variant in LTBR on chromosome 12p13.31: the nucleotide change (C→A at position 6386109, GRCh38) does not alter the alanine at protein position 172, but synonymous variants are not necessarily silent. They can affect codon usage and translation kinetics²² codon usage and translation kinetics
Different codons for the same amino acid are translated at different speeds; slower translation at critical points can alter how the protein folds co-translationally, mRNA stability, and splicing efficiency — mechanisms that have been documented for synonymous SNPs in other immune-receptor genes.

The Mechanism

LTBR receives signals from two main ligands: the lymphotoxin-αβ heterodimer (LTα1β2) secreted by activated T and B cells, and LIGHT (TNFSF14) expressed on activated T cells and NK cells. Upon ligation, LTBR activates two parallel NF-κB pathways³³ NF-κB pathways
NF-κB is a master transcription factor controlling inflammation, immune development, and cell survival — LTBR uniquely activates both the canonical (RelA/p50) and the non-canonical (RelB/p52) arms. The canonical arm drives acute inflammatory gene expression (IL-8, chemokines). The non-canonical arm, requiring NIK and IKKα, controls expression of chemokines (CXCL13, CCL19, CCL21) that recruit and position lymphocytes for optimal antigen encounters. This non-canonical pathway is also responsible for LTBR's critical role in lymph node organogenesis and tertiary lymphoid structure formation.

In rheumatoid arthritis, LTBR is overexpressed in synovial tissue⁴⁴ LTBR is overexpressed in synovial tissue
In one study correlating synovial cytokine expression with clinical measures, LTBR mRNA positively correlated with TNF-α, IFN-γ, and IL-15 levels, suggesting a feedback amplification loop in inflamed joints, where excess LTBR signaling drives formation of ectopic lymphoid tissue (ELT) — structures resembling lymph nodes that sustain local autoimmune responses. In IgA nephropathy, LTBR protein is detected in renal tubular epithelial cells and glomeruli⁵⁵ LTBR protein is detected in renal tubular epithelial cells and glomeruli
Induction of LTβ mRNA was identified in microarrays from both IgAN and lupus nephritis patients, and LTβR-Ig treatment attenuated nephritis severity in animal models, where it drives local NF-κB activation and renal inflammatory cascades.

The Evidence

The strongest genetic evidence for the LTBR locus in autoimmunity comes from a landmark GWAS of ankylosing spondylitis⁶⁶ GWAS of ankylosing spondylitis
The Australo-Anglo-American Spondyloarthritis Consortium (TASC) and Wellcome Trust Case Control Consortium 2 (WTCCC2) combined ~10,000 AS patients and controls in the largest AS genetic study at the time: the LTBR-TNFRSF1A region on chromosome 12p13 was associated with AS at genome-wide significance (rs11616188, combined P=4.1×10⁻¹²). This implicates the LTBR locus — not a single variant, but a chromosomal neighborhood of immune-signaling genes — in the genetic architecture of spondyloarthropathy.

For rs2364480 specifically, a Korean pediatric study⁷⁷ Korean pediatric study
199 children with biopsy-confirmed IgA nephropathy and 289 age-matched controls, genotyped by direct sequencing found the C allele of rs2364480 nominally associated with IgAN risk (p=0.041). The haplotype analysis was stronger: the TAA haplotype spanning rs3759333, rs3759334, and rs2364480 was significantly associated with IgAN (p=0.008 codominant). These findings are modest in isolation — a single study in one population with borderline p-values — but they are biologically coherent with the known role of LTBR in renal inflammation and the GWAS evidence at the broader locus.

Therapeutically, baminercept⁸⁸ baminercept
A fusion protein of the LTβR extracellular domain with human IgG1 Fc; it acts as a decoy receptor, capturing lymphotoxin and LIGHT before they reach cell-surface LTBR — an LTβR-Ig fusion protein — was tested in a Phase II RCT for primary Sjögren's syndrome (52 patients, 24 weeks). While baminercept mechanistically reduced CXCL13 and altered B/T cell trafficking consistent with LTβR blockade, it did not significantly improve glandular endpoints. This underscores the complexity of LTBR signaling in established autoimmune disease, but also validates that LTBR is a genuine pharmacological target in this pathway.

Practical Implications

Carriers of the CC genotype (the minor/risk genotype at ~4% frequency globally) carry two copies of the less-common C allele, which in the haplotype context associates with modestly altered LTBR signaling and nominal IgAN susceptibility in the published literature. For heterozygous AC carriers (~31%), the evidence for any clinically meaningful impact is limited; the current data support a monitoring posture rather than active intervention. For the common AA genotype (~65%), the population default — normal LTBR signaling and no signal for elevated autoimmune risk from this specific variant.

Interactions

rs2364480 sits within a haplotype block studied alongside the LTBR promoter variants rs3759333 (-1387C/T) and rs3759334 (-1326A/G). The TAA haplotype (rs3759333-T / rs3759334-A / rs2364480-A, using the Korean study's minor-allele notation) showed the strongest IgAN association (p=0.008), suggesting these three variants act together to modulate LTBR promoter activity and coding-region translational efficiency. The existing LTBR catalog entry rs10849448 (a 5'UTR regulatory variant with strong evidence for infection susceptibility) represents a distinct functional signal at the same gene — the two variants are not in tight LD and likely affect different aspects of LTBR biology.

The LTBR-TNFRSF1A chromosomal neighborhood (12p13) is a genetic hub for TNF-superfamily signaling. Carriers of risk alleles at TNFRSF1A (rs4149584, encoding R92Q in TNF receptor 1) combined with rs2364480 CC may face a compounded deficit in TNF-family receptor regulation — a proposed compound action candidate warranting future investigation.

Aromatase¹¹ Aromatase
the enzyme encoded by CYP19A1 that catalyzes the final and rate-limiting step of estrogen biosynthesis, converting androgens such as androstenedione and testosterone to estrogens is expressed in the ovaries, adipose tissue, bone, brain, and adrenal glands. Because it is the only enzyme capable of estrogen synthesis in vertebrates, even small changes in its expression can meaningfully shift the androgen–estrogen balance. The rs2414096 variant lies in intron 4 of CYP19A1 on chromosome 15 and does not alter the protein sequence, but several lines of evidence suggest it may influence aromatase expression levels or transcript regulation, with downstream effects on androgen-to-estrogen conversion.

The Mechanism

As an intronic variant, rs2414096 does not directly alter aromatase enzyme structure. Instead, it may act through effects on splicing efficiency, mRNA stability, or linkage disequilibrium with nearby regulatory elements. CYP19A1 is a complex locus with multiple tissue-specific promoters controlling aromatase expression in different organs; intronic variants can modulate these promoter activities in tissue-specific ways. The variant is located on chromosome 15 at position 51,237,582 (GRCh38), within intron 4, and CYP19A1 itself is transcribed from the minus strand²² CYP19A1 itself is transcribed from the minus strand. The GRCh38 reference allele (G) — corresponding to a C on the coding strand — appears to be the allele associated with lower aromatase activity based on multiple functional and association studies.

The Evidence

The primary evidence base consists of association studies across multiple populations, two meta-analyses, and a study linking this variant to direct hormone-level differences.

A 2021 meta-analysis of seven studies (1,414 PCOS cases, 1,276 controls) by Sharma et al.³³ A 2021 meta-analysis of seven studies (1,414 PCOS cases, 1,276 controls) by Sharma et al.
CYP19 gene rs2414096 variant and differential genetic risk of polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol 2021 found that the GG dominant model (GG+GA vs AA) was significantly associated with PCOS risk (OR=1.60, 95% CI 1.10–2.31, p=0.01), with the overall A-allele effect estimate of OR=0.74 (95% CI 0.62–0.88, p=0.0008), indicating the A allele is protective. The association was statistically significant in non-Indian populations but not Indian subpopulations, where genetic diversity is greater.

However, a larger 2022 meta-analysis by Xing et al. of 26 studies (4,860 PCOS cases, 4,043 controls)⁴⁴ a larger 2022 meta-analysis by Xing et al. of 26 studies (4,860 PCOS cases, 4,043 controls)
The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility. Front Physiol 2022 found no statistically significant overall association (OR=0.87, p=0.578) with extreme heterogeneity (I²=95.9%), underscoring that this variant's effects are genuinely population-dependent rather than universal.

Genotype-specific hormone data strengthen the mechanistic case. An analysis of 394 Kashmiri PCOS patients and 306 controls found that the GG genotype was associated with significantly elevated DHEAS, androstenedione, testosterone, and free androgen index⁵⁵ An analysis of 394 Kashmiri PCOS patients and 306 controls found that the GG genotype was associated with significantly elevated DHEAS, androstenedione, testosterone, and free androgen index
Ashraf et al. 2021. Impact of rs2414096 polymorphism of CYP19 gene on susceptibility of polycystic ovary syndrome and hyperandrogenism in Kashmiri women. Sci Rep 2021 (all comparisons p<0.05), supporting the hypothesis that the G allele reduces aromatase-driven androgen conversion. Similarly, a South Indian study of 150 PCOS patients found GG more prevalent among cases, with elevated LH/FSH ratios in GG carriers, and concluded that GG may exhibit reduced aromatase activity with subsequent hyperandrogenism⁶⁶ South Indian study of 150 PCOS patients found GG more prevalent among cases, with elevated LH/FSH ratios in GG carriers, and concluded that GG may exhibit reduced aromatase activity with subsequent hyperandrogenism
Hegde et al. 2023. Delineating the role of single-nucleotide polymorphism of CYP19 gene on aromatase activity in South Indian women with PCOS. J Genet Eng Biotechnol 2023.

On the question of circulating hormones, the SWAN study of 1,538 multiethnic midlife women found that Caucasian women with the AA genotype had markedly lower SHBG levels after adjusting for age and BMI⁷⁷ the SWAN study of 1,538 multiethnic midlife women found that Caucasian women with the AA genotype had markedly lower SHBG levels after adjusting for age and BMI
Sowers et al. 2006. Aromatase gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am J Med 2006. Lower SHBG increases free testosterone bioavailability, which may appear directionally contradictory to the PCOS data above — it suggests AA carriers have higher free androgen exposure despite a proposed protective effect on PCOS. This likely reflects tissue-specific or context-specific aromatase regulation: ovarian aromatase activity and circulating SHBG regulation are influenced by different promoters and feedback mechanisms. Context matters, and a single intronic variant almost certainly does not have a unidirectional effect across all tissues simultaneously.

Practical Actions

For women with PCOS features — irregular cycles, hirsutism, elevated androgens, or anovulatory infertility — the GG genotype adds a modest piece of evidence supporting impaired androgen-to-estrogen conversion in the ovary. This reinforces evaluation of androgen levels alongside this genotype, and consideration of aromatase-relevant interventions when clinically appropriate. Letrozole (an aromatase inhibitor paradoxically used to stimulate ovulation in PCOS by briefly lowering estrogen feedback, prompting FSH surge) is the standard-of-care first-line ovulation induction agent in PCOS; whether this genotype modifies letrozole response is an open question with no prospective pharmacogenomic data yet.

The heterogeneous evidence means this variant should be interpreted in the context of clinical findings, not used as a standalone diagnostic marker.

Interactions

Rs2414096 is part of the CYP19A1 locus alongside rs700518 (Val80, synonymous variant affecting aromatase expression and AI side-effect risk), rs700519 (Arg264Cys, coding variant with increased catalytic activity in vitro), and rs1062033 (intronic regulatory variant with CEBPβ-mediated transcriptional effect on aromatase in bone). These variants form haplotypes and may have compounded effects on total aromatase expression and activity — their combined influence on androgen–estrogen balance in reproductive tissues, bone, and adipose tissue is likely greater than any individual variant's effect alone. Women carrying risk genotypes across multiple CYP19A1 loci may have a broader pattern of altered estrogen synthesis worth evaluating with comprehensive hormone panels.

The chromosome 5q35.2 region was one of four genome-wide significant loci first identified in the landmark 2009 GWAS of 17,438 women¹¹ GWAS of 17,438 women
He et al. 2009, Nature Genetics — the first genome-wide scan for menopause-timing variants. At the center of this locus sits UIMC1 (also called RAP80) — a BRCA1 adaptor protein — and nearby, approximately 71 kb downstream, ZNF346 (zinc finger protein 346, also known as JAZ). The intronic variant rs244715 in ZNF346 is a proxy SNP for this locus, in partial linkage disequilibrium with the index UIMC1 coding variant rs365132 (r²=0.677 in European populations). Each G allele at rs244715 may be associated with a modest shift toward earlier menopause onset.

The Mechanism

The 5q35.2 locus is anchored biologically by UIMC1 (ubiquitin interaction motif containing 1), a protein that physically interacts with BRCA1 and is required to recruit the BRCA1-A complex to sites of DNA double-strand breaks. This recruitment initiates G2/M checkpoint control²² G2/M checkpoint control
The G2/M checkpoint prevents cells with damaged DNA from dividing; failure of this checkpoint accelerates DNA damage accumulation in dividing cells and homologous recombination repair. Because oocytes are some of the most DNA-damage-sensitive cells in the body — they can arrest in meiosis for decades and are exposed to oxidative stress throughout a woman's reproductive life — efficient DNA repair is critical for maintaining follicular integrity. Impaired repair capacity at this locus may accelerate the rate at which follicles accumulate irreparable DNA damage, triggering apoptosis and depleting the ovarian reserve prematurely.

ZNF346 itself adds a plausible second layer. As a nucleolar zinc finger protein (also called JAZ — "just another zinc finger protein"), it preferentially binds double-stranded RNA rather than DNA, and has been shown to positively regulate p53 transcriptional activity³³ positively regulate p53 transcriptional activity
p53 is a master regulator of cellular stress responses; when p53 is activated, it can trigger cell-cycle arrest or apoptosis depending on context, mediating G1 cell-cycle arrest and apoptosis. ZNF346 is expressed in ovarian tissue (11.9 nTPM, Human Protein Atlas) and at notably higher levels in granulosa cells (21.1 nCPM), the somatic cells that nurse follicles and regulate their fate. Altered ZNF346 expression — potentially driven by the eQTL effects of the 5q35.2 haplotype — may modulate granulosa cell survival and follicular apoptosis thresholds. Whether rs244715 itself directly alters ZNF346 expression or function in the ovary remains under investigation.

Separately, a 2021 study found that rs244715 was associated with anti-Hsp27 antibody titers⁴⁴ anti-Hsp27 antibody titers
Heat shock protein 27 (Hsp27) is a stress-response chaperone; elevated anti-Hsp27 antibodies are a marker of immune activation and oxidative stress in premature menopause cases, suggesting a possible inflammatory or oxidative-stress component to this variant's effect on ovarian aging.

The Evidence

The 5q35.2 locus has been replicated in multiple large-scale studies. The He et al. 2009 discovery GWAS⁵⁵ He et al. 2009 discovery GWAS
n=17,438 women, European ancestry; four menopause loci identified at p<1×10⁻⁷ was confirmed by the Stolk et al. 2012 ReproGen meta-analysis⁶⁶ Stolk et al. 2012 ReproGen meta-analysis
n=38,968 discovery + 14,435 replication, 22 independent European-ancestry cohorts, which identified the 5q35.2 locus as one of 13 independent menopause-timing signals. The index variant rs365132 in UIMC1 had a beta of approximately 0.29 years (~15 weeks) per minor allele in the original discovery cohort.

The Breakthrough Generations Study⁷⁷ Breakthrough Generations Study
Murray et al. 2011, Hum Mol Genet, n=2,007 women including 694 early menopause cases; UK prospective cohort directly evaluated rs244715 and found the G allele yields an OR of 1.20 (95% CI 1.09–1.32, p=1.7×10⁻⁴) for early menopause (defined as menopause before age 46). Women homozygous for risk alleles across all four 2009 GWAS loci (including rs244715 GG) had approximately 4-fold higher odds of early menopause than women with three or fewer risk alleles. The per-allele effect on age at menopause in this study was 0.059 years, though this did not reach significance in the smaller quantitative trait analysis.

The Mashhad premature ovarian insufficiency cohort⁸⁸ Mashhad premature ovarian insufficiency cohort
Ziaee et al. 2021, 117 POI cases vs. 183 controls; Iranian women found allelic association of rs244715 G with POI (OR 1.71, 95% CI 1.17–2.50, p=0.005). The homozygote contrast (GG vs. AA) had an OR of 3.93 (95% CI 1.40–11.00, p=0.009) — a large effect consistent with an additive architecture — though none of these associations survived Bonferroni correction for the eight SNPs studied. The 5q35.2 locus was further extended in the Day et al. 2015 expanded GWAS⁹⁹ Day et al. 2015 expanded GWAS
n~70,000 European women; 54 independent signals in 44 genomic regions identified, confirming this as a durable, replicated signal.

Multi-ethnic replication is incomplete. The PAGE study¹⁰¹⁰ PAGE study
Carty et al. 2013, multi-ethnic US cohorts found rs365132 (the UIMC1 index SNP) significantly replicated in non-European populations, though the LD structure at the locus varies substantially across ancestries, meaning rs244715 may be a less reliable proxy in non-European groups.

Practical Implications

With an estimated per-allele shift of roughly 2–3 weeks in menopause timing, rs244715 has a modest individual effect. Its clinical utility lies in contributing to a polygenic burden score for ovarian aging — when combined with other replicated loci (MCM8 rs16991615, PRRC2A rs1046089, FNDC4 rs2303369), the cumulative genetic signal becomes more predictive of early reproductive aging than any single variant.

For women with the GG genotype who are considering when to start their family or whether to investigate fertility preservation, this variant is most informative when interpreted alongside AMH (anti-Müllerian hormone) levels — the most sensitive biomarker of remaining ovarian reserve — and antral follicle count on ultrasound.

The DNA repair context of this locus also raises a plausible lifestyle modulator: oxidative stress is a key driver of follicular DNA damage, and the 5q35.2 locus mechanism suggests that factors increasing cellular oxidative load (smoking, chronic inflammation) may interact with reduced UIMC1/ZNF346 pathway efficiency. However, there is currently no published evidence directly testing this gene-environment interaction.

Interactions

UIMC1 rs365132: The biological index SNP at this locus. rs244715 and rs365132 are in partial LD (r²=0.677 in Europeans), meaning they are highly correlated but not perfectly interchangeable. rs365132 (a synonymous UIMC1 coding variant) is the more functionally annotated variant and may be a better proxy for the biological effect at this locus. If a user has both, interpret the more significant association; they should not be treated as independent signals.

MCM8 rs16991615 (E341K): The strongest-effect DNA repair locus for menopause timing (~1 year per allele). Both MCM8 and the UIMC1/ZNF346 locus operate through overlapping DNA repair pathways (MCM8: replication fork restart; UIMC1: BRCA1-mediated DSB repair). A woman carrying risk alleles at both loci has two independent DNA-repair hits on reproductive lifespan. The combined signal may warrant earlier AMH baseline assessment.

A proposed compound action: Women who carry GG at rs244715 and carry the risk genotype at MCM8 rs16991615 (GG, associated with earlier menopause/lower AMH) represent an additive polygenic burden from two independent DNA-repair loci. The combined recommendation would be to obtain a baseline AMH panel before age 30, with repeat testing at 2-year intervals, and to discuss reproductive timeline planning with a reproductive endocrinologist if AMH is trending below age-expected norms.

PRRC2A rs1046089: A distinct menopause-timing locus on chromosome 6 operating through an immune/HLA pathway rather than DNA repair. rs244715 and rs1046089 are on different chromosomes and have no LD relationship — they are independent signals. Carrying risk alleles at both would represent additive contributions from two biologically distinct pathways (DNA repair and immune-mediated follicle depletion) to earlier ovarian aging.

Von Willebrand factor (VWF) is a multimeric glycoprotein essential for primary hemostasis. Under shear stress — in the turbulent flow of small vessels or at a wound site — ultra-large VWF multimers unfurl to capture platelets via their GPIb receptors, forming the platelet plug that stops bleeding before coagulation factors reinforce it. The size of the multimer matters: only the high-molecular-weight (HMW) forms¹¹ high-molecular-weight (HMW) forms
The largest VWF multimers carry the most platelet-binding A1 domains and collagen-binding A3 domains; their loss cannot be compensated by increased total VWF antigen are mechanically competent to bridge platelets to collagen under flow. The Y1146C variant in the D3 domain knocks out precisely those critical large forms, producing von Willebrand disease type 2A/IIE — and it does so in a single heterozygous copy.

The Mechanism

The VWF gene on chromosome 12p13.31 encodes a 2,813-amino-acid pre-pro-protein. After signal peptide cleavage and propeptide removal, mature VWF subunits dimerize and then multimerize²² dimerize and then multimerize
VWF dimerizes head-to-tail via C-terminal CK domain disulfide bonds in the endoplasmic reticulum, then multimerizes head-to-head via N-terminal disulfide bonds — forming chains of 20–40+ subunits stored in Weibel-Palade bodies through precisely orchestrated disulfide bonding in the D3 domain.

The Y1146C substitution introduces a rogue cysteine residue³³ introduces a rogue cysteine residue
Tyr1146 is normally a hydroxyl-bearing aromatic residue. Replacing it with cysteine adds a free thiol that forms aberrant disulfide bonds, disrupting local D3 domain folding into the D3 domain — the very region that mediates the initial head-to-head multimerization steps. In vitro expression studies confirm that Y1146C-mutant VWF shows severe reduction in or complete absence of HMW monomers⁴⁴ Y1146C-mutant VWF shows severe reduction in or complete absence of HMW monomers
Recombinant expression of Y1146C demonstrated intracellular retention of most mutant protein and failure to secrete HMW forms, with decreased secreted VWF antigen levels. The dominant-negative effect of one misfolded allele is sufficient to deplete large multimers from plasma.

The resulting multimer profile is the laboratory hallmark of type 2A VWD: normal or mildly reduced VWF antigen, but complete absence of the large and intermediate multimers on gel electrophoresis. VWF ristocetin cofactor activity (VWF:RCo) is disproportionately reduced relative to antigen — the ratio that distinguishes qualitative defects from simple quantitative deficiency.

The Evidence

Schneppenheim and colleagues⁵⁵ Schneppenheim and colleagues
Blood 2010, 115:4894–4901; 57 patients from 38 unrelated families with type 2A/IIE multimer pattern identified a cluster of 22 mutations in the VWF D3 domain responsible for a distinct type 2A subgroup (previously described in single families as type IIE). Y1146C was by far the most common, found in 12 of 38 probands (32%). Most mutations in this cluster affect cysteine residues — either creating new cysteines (like Y1146C) or destroying existing ones — consistent with the central role of disulfide bond architecture in D3 domain function. Pathogenicity was confirmed by expression studies and phenotypic characterization of recombinant mutant proteins.

Clinical presentation among Y1146C carriers ranged from mild to severe mucocutaneous bleeding, reflecting the heterogeneity typical of type 2A: epistaxis, easy bruising, prolonged bleeding after dental procedures, heavy menstrual bleeding, and postoperative hemorrhage. The variable expressivity likely reflects contributions from modifier genes, blood type O (which lowers VWF levels by ~25%), and acquired factors.

Therapeutic responsiveness to desmopressin (DDAVP) in type 2A VWD is mutation-dependent⁶⁶ desmopressin (DDAVP) in type 2A VWD is mutation-dependent
A 2022 study of 250 VWD patients showed only 31% of type 2 patients achieve complete DDAVP response; response is highly variant-specific and can be predicted by genotype. For D3-cluster mutations like Y1146C, even when VWF antigen rises after DDAVP infusion, the released VWF lacks HMW multimers and functional activity remains impaired — making VWF concentrate the preferred treatment modality for this variant.

Practical Actions

The 2021 ASH/ISTH/NHF/WFH guidelines⁷⁷ 2021 ASH/ISTH/NHF/WFH guidelines
Joint guidelines from four major hematology/hemostasis societies providing evidence-based management for all VWD subtypes recommend that type 2A patients requiring hemostasis support receive VWF concentrate rather than desmopressin as first-line therapy, particularly for surgical prophylaxis and major bleeding. Tranexamic acid (an antifibrinolytic) serves as an effective adjunct for mucosal bleeding and minor procedures. Women with heavy menstrual bleeding benefit from hormonal therapy (combined oral contraceptives or progestin-only) or tranexamic acid.

All carriers — including those with mild phenotypes — should have their bleeding history formally assessed and be evaluated by a hematologist experienced in bleeding disorders. A formal DDAVP trial with multimer analysis before and after infusion determines individual responsiveness and informs pre-procedural planning.

Interactions

Blood type O is a significant modifier: O-type individuals have approximately 25% lower VWF levels at baseline, which compounds with the multimer loss from Y1146C to produce more severe bleeding phenotypes. Patients with blood group O and Y1146C may present with more pronounced laboratory abnormalities and symptom burden than AB-type carriers.

Factor V Leiden (rs6025) and the prothrombin G20210A variant (rs1799963) can partially counterbalance a mild bleeding diathesis in Y1146C carriers — though this interaction is theoretical rather than clinically well-documented, and coexisting thrombophilia in a VWD patient complicates management substantially.

Most coagulation variants are straightforward: a gene changes, clotting goes up or down. Factor XII defies that logic. The gene at the heart of the contact activation pathway¹¹ contact activation pathway
the intrinsic coagulation cascade triggered when blood contacts foreign surfaces or negatively charged molecules was long thought inconsequential in humans — people completely lacking Factor XII don't bleed abnormally. Yet elevated Factor XII levels turn out to be an independent cardiovascular risk factor, and recent large-scale genomic data confirm that genetically lower Factor XII is protective against thrombosis. The rs2731672 variant in the F12 locus is the most replicated genetic determinant of Factor XII activity levels, explaining more variance in the clotting test aPTT than almost any other common variant.

The Mechanism

rs2731672 sits at chr5:177,415,473 (GRCh38), approximately 7 kilobases downstream of the F12 gene. It is in strong linkage disequilibrium with rs1801020, the well-characterized F12 C46T variant in the 5'-untranslated region of the gene. The C46T change impairs translation efficiency of Factor XII protein — fewer ribosomes successfully initiate translation from the modified UTR, reducing secreted Factor XII levels. The rs2731672 T allele tags this low-expression haplotype, so carriers of TT have substantially lower circulating Factor XII than CC homozygotes.

Factor XII initiates the contact activation cascade by autoactivating on negatively charged surfaces (collagen, polyphosphates, nucleic acids released from activated platelets and dying cells). Activated Factor XII (FXIIa) then activates Factor XI, ultimately generating thrombin and a fibrin clot. Paradoxically, although complete FXII deficiency causes isolated prolonged aPTT with no bleeding tendency, elevated FXIIa correlates with heightened coagulation tone, higher fibrinopeptide A (a marker of active fibrin formation), and increased coronary disease risk.

Additionally, rs2731672 maps to the kallikrein-kinin system region alongside KLKB1 (plasma kallikrein). A GWAS of vasoactive peptide levels²² A GWAS of vasoactive peptide levels
Verweij et al., Hypertension 2013 identified strong epistatic interactions between rs2731672 and the KLKB1 variant rs4253238 for plasma levels of adrenomedullin and endothelin-1 precursors — two vasoregulatory peptides that independently predict cardiac death and heart failure — adding a vascular tone dimension to the FXII story.

The Evidence

The genetic architecture of Factor XII levels was established by a GWAS in two Scottish birth cohorts (n=1,477)³³ GWAS in two Scottish birth cohorts (n=1,477)
Houlihan et al., Am J Hum Genet 2010, which found rs2731672 to be the single most significant genetic determinant of aPTT (p=2.16×10⁻³⁰). Together with variants in KNG1 (high-molecular-weight kininogen) and HRG (histidine-rich glycoprotein), this three-SNP model explained approximately 18% of phenotypic variance in aPTT — a remarkably large fraction for complex trait GWAS, reflecting the strong genetic control over Factor XII expression.

The cardiovascular consequences of FXII activity levels were clarified in a prospective study of 2,624 middle-aged Scottish men⁴⁴ prospective study of 2,624 middle-aged Scottish men
Lowe et al., Circulation 2000, which measured plasma FXIIa (activated Factor XII) and followed men for coronary heart disease over several years. Men in the highest third of FXIIa concentration had a hazard ratio of 1.96 for CHD compared to the lowest third (P=0.007) — nearly a doubling of risk. Genotype strongly predicted FXIIa: CC carriers averaged 2.0 ng/mL, CT intermediate at 1.4 ng/mL, and TT the lowest at 0.8 ng/mL. Higher FXIIa also correlated with elevated fibrinopeptide A, confirming active coagulation cascade engagement in vivo.

The WOSCOPS statin trial (n=6,595 hypercholesterolaemic men)⁵⁵ WOSCOPS statin trial (n=6,595 hypercholesterolaemic men)
Koch et al., Atherosclerosis 2002 added a pharmacogenomic dimension: men with the high-FXII CC genotype showed significant cardiovascular benefit from pravastatin (OR 0.76 for CHD), while those with the low-FXII TT genotype did not benefit from statin therapy. This interaction suggests the FXIIa pathway and the LDL-mediated atherosclerotic pathway interact, and that lipid lowering is particularly valuable for individuals whose genotype sustains high contact activation tone.

The largest and most definitive evidence comes from a 2025 population-scale analysis in 703,745 participants⁶⁶ population-scale analysis in 703,745 participants
Lorentz et al., Nat Commun 2025 showing that heterozygous F12 loss-of-function variant carriers are protected against venous thromboembolism without any increased risk of bleeding complications or infection — validating Factor XII as a safe therapeutic target and confirming that lower FXII is genuinely protective.

Practical Actions

For CC homozygotes, the main implication is heightened thrombotic risk through the contact activation pathway. This is not a pathway addressed by standard anticoagulants (warfarin, DOACs), which target the tissue factor pathway. The most relevant management strategies involve monitoring classical cardiovascular risk biomarkers (aPTT, fibrinogen), addressing other thrombotic risk factors, and being aware of the potential for increased clotting risk with factors that activate the contact pathway (e.g., foreign surfaces during surgery, implanted devices, or severe inflammatory states).

For TT homozygotes — particularly common in East Asian populations — the genotype confers a natural reduction in coagulation tone that appears to be protective against both arterial and venous thrombotic events, with no apparent cost in terms of bleeding or infection risk.

Interactions

rs2731672 is in strong LD with rs1801020 (F12 5'-UTR C46T), the primary functional variant affecting Factor XII translation. These two SNPs essentially tag the same biological signal and should not be double-counted.

The epistatic relationship with rs4253238 in KLKB1 (plasma kallikrein, the immediate downstream activator of Factor XII in the contact pathway) is well-documented for vasoactive peptide levels. Carriers of low-activity haplotypes at both F12 and KLKB1 may have compounded reduction in contact activation and are candidates for the most favorable thrombosis-protective profile, while those with high-activity alleles at both loci may have the highest contact-pathway-mediated clotting risk.

SLC45A2 encodes a melanosomal membrane-associated transporter protein¹¹ melanosomal membrane-associated transporter protein
MATP, which regulates melanosomal pH critical for tyrosinase activity that controls melanin synthesis. The rs28777 variant is an intronic SNP in SLC45A2 that emerged from a genome-wide association study of over 10,000 Europeans²² genome-wide association study of over 10,000 Europeans
Han et al. 2008, PLoS Genetics as one of the most statistically significant markers for human pigmentation variation. While the nearby missense variant rs16891982 (L374F) is the likely causal variant in this gene, rs28777 independently tags SLC45A2 haplotypes that track skin, hair, and eye pigmentation across global populations.

The Mechanism

As an intronic variant, rs28777 does not directly alter the SLC45A2 protein sequence. Instead, it sits within a haplotype block that encompasses regulatory elements influencing SLC45A2 expression levels. The derived A allele occurs on haplotypes associated with reduced SLC45A2 transporter activity, leading to altered melanosomal pH³³ altered melanosomal pH
more acidic melanosomal environment impairs tyrosinase copper binding and reduces eumelanin synthesis. This results in lower eumelanin (brown-black pigment) production, lighter constitutive pigmentation, and reduced natural photoprotection against ultraviolet radiation. The ancestral C allele maintains haplotypes supporting efficient melanin synthesis and darker pigmentation.

The A allele shows one of the most extreme population frequency differentials in the human genome: approximately 95% in Europeans but only 12% in East Asians and 19% in Africans. This pattern reflects strong positive selection for depigmentation⁴⁴ strong positive selection for depigmentation
selective sweep over the past 5,000-20,000 years favoring vitamin D synthesis at high latitudes as human populations migrated to northern latitudes with lower UV radiation.

The Evidence

The initial GWAS by Han et al.⁵⁵ Han et al.
multi-stage study of natural hair color in European ancestry identified rs28777 with genome-wide significant associations for hair color (pooled P = 8.9 x 10^-14), tanning ability (pooled P = 2.2 x 10^-10), and skin color (pooled P = 9.5 x 10^-4). The minor C allele in Europeans was associated with darker hair, darker skin, and stronger tanning response.

In a large Australian population-based case-control study⁶⁶ large Australian population-based case-control study
1,716 melanoma cases and 4,111 controls, rs28777 exhibited one of the strongest crude associations with cutaneous melanoma risk among all pigmentation variants tested (allelic OR 3.75, P < 1.0 x 10^-4). After adjustment for Northern European ancestry, the effect attenuated to OR 2.37 (P = 0.0012), and after further adjustment for pigmentary phenotype, OR 1.68 (P = 0.045). Multivariable analysis adjusting for rs16891982 rendered rs28777 non-significant, confirming strong linkage disequilibrium between the two SLC45A2 variants and suggesting rs16891982 is the primary functional driver.

A review and meta-analysis of GWAS for pigmentation and skin cancer⁷⁷ review and meta-analysis of GWAS for pigmentation and skin cancer
Sturm 2009 reported rs28777 associated with skin color at P = 1.2 x 10^-17 in a South Asian population study, placing it among the most significant pigmentation loci genome-wide. The combined evidence across multiple studies of SLC45A2 and melanoma⁸⁸ multiple studies of SLC45A2 and melanoma
meta-analyses in Southern European populations establishes this gene region as a bona fide melanoma susceptibility locus with genome-wide epidemiological credibility.

Collectively, pigmentation gene polymorphisms including SLC45A2 variants account for approximately 12% of familial melanoma risk⁹⁹ pigmentation gene polymorphisms including SLC45A2 variants account for approximately 12% of familial melanoma risk
in high-UV European-descent populations, underscoring the direct pathway from pigmentation genetics to cancer susceptibility.

Practical Implications

Your rs28777 genotype reflects your SLC45A2 haplotype background and correlates with your constitutive pigmentation level, tanning capacity, and UV vulnerability. Individuals homozygous for the A allele have the lightest baseline pigmentation, the weakest tanning response, and the highest susceptibility to UV-induced DNA damage. Those carrying one or two C alleles have progressively more melanin production, better tanning ability, and greater intrinsic photoprotection.

For AA carriers, rigorous photoprotection is medically indicated. Use broad-spectrum sunscreen SPF 30+¹⁰¹⁰ broad-spectrum sunscreen SPF 30+
blocks 97% of UVB radiation on all exposed skin daily, seek shade during peak UV hours (10 AM - 4 PM), and wear protective clothing including wide-brimmed hats and UV-blocking sunglasses. Annual dermatological screening enables early detection of suspicious lesions when treatment is most effective.

Interactions

rs28777 is in strong linkage disequilibrium with rs16891982 (SLC45A2 L374F), the missense variant that directly alters melanosomal transporter function. The two variants track overlapping but not identical haplotypes, and rs28777 provides additional tagging of SLC45A2 regulatory variation beyond what rs16891982 captures alone.

SLC45A2 variants interact epistatically with MC1R red hair color variants (rs1805007, rs1805008) to modulate melanoma risk. Individuals carrying MC1R risk alleles have decreased melanoma risk if they concurrently carry SLC45A2 dark-pigmentation alleles, as higher melanin synthesis partially offsets the impaired tanning response caused by MC1R variants.

Additional epistatic interactions have been documented with OCA2 (rs12913832), TYR (rs1042602), SLC24A5 (rs1426654), and ASIP (rs6058017). The combined effect of multiple light-pigmentation alleles across these loci compounds melanoma susceptibility beyond simple additive models, making multi-locus pigmentation profiling more informative than any single variant alone.

Interleukin-10 (IL-10) is the immune system's master brake pedal. Without adequate IL-10, the body's inflammatory responses run longer and harder than necessary — a pattern that underlies conditions ranging from inflammatory bowel disease to asthma to susceptibility to bacterial infections. rs3024491 sits in intron 2 of the IL10 gene¹¹ intron 2 of the IL10 gene
A non-coding region within the gene's second intron, located at chromosome 1q32.1, and functions as an independent regulatory switch distinct from the well-studied promoter haplotypes (rs1800896, rs1800871, rs1800872). IL10 is encoded on the minus (reverse) strand, so while genome files report the plus-strand C and A alleles, the published literature often describes the complementary G and T alleles — the A allele here corresponds to what many papers call the T allele.

The Mechanism

Because rs3024491 lies within an intron rather than the coding sequence, it does not change the IL-10 protein structure. Instead, it influences how much IL-10 gets produced. Intronic variants can affect gene expression through several mechanisms²² gene expression through several mechanisms
Including altered splicing efficiency, disruption of intronic enhancer elements, and changes to RNA secondary structure that affect transcript stability. The A allele (coding-strand T) reduces IL-10 output, while the common C allele maintains normal production. This regulatory effect is independent of the promoter haplotype system — meaning someone with a "normal" promoter can still carry the intronic A allele and produce less IL-10 than expected.

The functional consequence is a shift in immune tone. Lower IL-10 means the immune system is slower to call off its inflammatory response after infection or tissue injury. In the gut, this creates conditions where the mucosal immune system is more reactive to the normal commensal bacteria — a central feature of inflammatory bowel disease. In the airway, it means allergen-triggered inflammation resolves more slowly. In the stomach, it may allow H. pylori³³ H. pylori
A bacteria that colonizes ~50% of people globally, causing gastric inflammation and long-term risk of gastric ulcer and cancer to establish infection more easily, partly because the bug itself exploits IL-10 to dampen host defenses.

The Evidence

The strongest functional data comes from a Brazilian pediatric study examining 123 asthmatic children and 58 controls⁴⁴ examining 123 asthmatic children and 58 controls
Assis et al. 2021, Association between interleukin-10 polymorphisms and CD4+CD25+FOXP3+ T cells in asthmatic children, published in the Journal of Investigational Allergology and Clinical Immunology. The AA genotype (TT in coding-strand notation) was associated with significantly reduced IL-10 serum levels (p = 0.01) and a higher frequency of regulatory T cells (p = 0.01). The A allele appeared more often in children with moderate asthma compared to mild asthma or controls (71.4% vs. 48.5%, p = 0.042), identifying rs3024491 as the most consistently significant of the four IL-10 polymorphisms studied.

A Brazilian birth-cohort study of 1,259 children aged 4–11 years⁵⁵ aged 4–11 years
Assis et al. 2014, IL10 SNPs related to upregulation of constitutive IL-10 production and H. pylori susceptibility, published in Helicobacter found that carriers of the A allele had significantly increased susceptibility to H. pylori infection (OR = 1.71; 95% CI 1.14–2.57, p = 0.01), associated with higher constitutive IL-10 production in culture — a counterintuitive finding suggesting the variant may modulate infection-triggered immune suppression rather than simply lowering baseline IL-10 uniformly.

A Tunisian study on cervical cancer susceptibility⁶⁶ cervical cancer susceptibility
Barbouche et al. 2015, IL-10 gene promoter and intron polymorphisms as genetic biomarkers, published in Cytokine confirmed that the minor allele of rs3024491 was associated with reduced IL-10 secretion, consistent with the mechanistic picture of the A allele as a low-producer variant.

At the locus level, the IL10 region on chromosome 1q32 is one of the most robustly replicated IBD susceptibility loci in GWAS, achieving p = 1.35 × 10⁻¹² for ulcerative colitis in the landmark 2008 Nature Genetics study. The lead GWAS SNP (rs3024505, ~5 kb downstream of IL10) is in linkage disequilibrium with intronic variants including rs3024491, and conditional analyses suggest multiple independent signals across the locus. rs3024491's independently documented effect on IL-10 output makes it a biologically plausible contributor to this susceptibility architecture.

Practical Actions

The A allele's reduced IL-10 output creates a more pro-inflammatory baseline that is particularly relevant for gut health and respiratory inflammation. Anti-inflammatory dietary strategies can partially compensate: omega-3 fatty acids (EPA/DHA) have documented IL-10-upregulating effects, curcumin activates IL-10 transcription via NF-κB modulation, and vitamin D supports IL-10 production in regulatory T cells. For anyone with AA genotype who develops gastrointestinal symptoms, early evaluation for inflammatory bowel disease is warranted — the diagnostic delay for IBD averages years, and genetic awareness can prompt earlier investigation.

H. pylori infection is worth testing for in A allele carriers, especially those with dyspepsia or a family history of gastric disease, as eradication therapy eliminates a major chronic inflammatory stimulus that low IL-10 producers handle less efficiently.

Interactions

rs3024491 operates as an independent layer of IL-10 regulation on top of the promoter haplotype system defined by rs1800896, rs1800871, and rs1800872. Carriers of both the intronic A allele at rs3024491 and the low-producing promoter haplotype (ATA, defined by the A allele at rs1800896) face compound reduction in IL-10 transcription from two distinct regulatory elements. This stacked low-producer state is likely to show stronger effects on IBD susceptibility and inflammatory disease severity than either variant alone — though direct compound studies are limited. The two regulatory systems should be considered together when assessing overall IL-10 production capacity.

Every antibody that defends you against a repeated infection — from the IgA that coats your gut to the IgG that neutralises a pathogen in your blood — depends on a molecular conversation between B cells and their survival signals. TACI (Transmembrane Activator and Calcium modulator and cyclophilin ligand Interactor)¹¹ TACI (Transmembrane Activator and Calcium modulator and cyclophilin ligand Interactor)
TACI is encoded by TNFRSF13B and expressed mainly on mature B cells and plasma cells; it binds the cytokines BAFF and APRIL to regulate B-cell differentiation, class-switch recombination, and immunoglobulin secretion is the receptor that receives those survival signals. The C104R variant (rs34557412) swaps a cysteine for an arginine at position 104 in TACI's ligand-binding domain — precisely the cysteine residue that forms a disulfide bridge required for proper receptor folding. The result is a malformed receptor that cannot bind its ligands and, more dangerously, actively sabotages the wild-type copies it assembles with.

This makes C104R the most consequential known non-HLA risk factor for infection susceptibility and the most penetrant genetic cause of common variable immunodeficiency (CVID). It is rare — about 1% of Europeans carry one copy — but the functional consequences in carriers are measurable at the population level and clinically serious in a subset.

The Mechanism

TACI forms oligomeric receptor complexes before ligand binding — the subunits pre-assemble in the membrane even before BAFF or APRIL arrives. This is critical for understanding why C104R is so damaging. Because the mutant receptor integrates into the same oligomeric complex as wild-type TACI, it cannot be simply ignored. Garibyan et al. demonstrated in 2007²² Garibyan et al. demonstrated in 2007
the dominant-negative effect was confirmed by co-immunoprecipitation in cells co-expressing WT and C104R TACI; the corresponding murine mutant C76R showed identical effects that C104R dominantly interferes with signaling by blocking ligand-induced receptor rearrangement — not by preventing ligand binding itself, but by freezing the oligomeric complex in a non-signaling conformation. A single mutant subunit can silence the entire receptor cluster.

The downstream consequences are predictable: without TACI signaling, B cells fail to undergo class-switch recombination³³ class-switch recombination
the process by which B cells change from producing IgM to producing IgG, IgA, or IgE — essential for producing antibodies tailored to the pathogen's surface. Without class switching, the adaptive immune response cannot generate the specific, high-affinity antibodies that prevent re-infection. B cells from C104R carriers express surface TACI normally but produce negligible IgG and IgA in response to APRIL stimulation. At the chromatin level, multi-omics analysis⁴⁴ multi-omics analysis
naïve B cells from C104R carriers showed 8% less accessible chromatin at baseline; class-switched memory B cells showed 25% less reveals a genome-wide silencing of B-cell activation programs — with dysregulated NF-κB and MAPK signalling confirmed by flow cytometry.

The Evidence

Discovery and CVID connection. Two concurrent Nature Genetics papers in 2005⁵⁵ Nature Genetics papers in 2005
Castigli et al. and Salzer et al. were published back-to-back and together established TNFRSF13B as the first non-HLA gene associated with CVID established TNFRSF13B mutations as a cause of CVID and IgA deficiency. Castigli et al. found TACI mutations in 4 of 19 CVID patients and 1 of 16 IgAD patients, absent in all 50 healthy controls. Salzer et al. identified mutations in 13 CVID patients, with homozygous C104R abolishing APRIL binding and class switching entirely. Combined population analysis found TNFRSF13B mutation frequency of 9.9% in CVID patients vs. 3.2% in controls⁶⁶ TNFRSF13B mutation frequency of 9.9% in CVID patients vs. 3.2% in controls
p<10⁻⁶ across Czech, Canadian, and European populations; C104R was the most frequent single mutation detected.

Infection susceptibility at the population level. A [genome-wide association study of

200,000 Europeans | Tian et al. Nature Communications 2017; 23 infection phenotypes tested including tonsillectomy, childhood ear infection, strep throat, pneumonia, and others](https://pubmed.ncbi.nlm.nih.gov/28928442/⁷⁷ https://pubmed.ncbi.nlm.nih.gov/28928442/) found rs34557412 to be the strongest non-HLA association with infection susceptibility, with an odds ratio of 1.59 (p=3×10⁻²¹) for tonsillectomy and nominally significant association with childhood ear infection (p=2×10⁻⁶). Tonsillectomy in this context is a proxy for recurrent tonsillitis — the tonsillar B-cell microenvironment is particularly dependent on TACI-mediated switching to IgA, and its failure manifests as chronic mucosal infections requiring surgical removal.

Blood cell effects. A large GWAS of haematological traits⁸⁸ large GWAS of haematological traits
Astle et al. Cell 2016; 127,000+ individuals from UK Biobank and other cohorts found significant associations between the G allele and reduced monocyte count (p=3×10⁻²⁷), reduced lymphocyte count (p=2×10⁻¹⁰), and reduced platelet count (p=2×10⁻¹¹). These effects reflect TACI's role in shaping the composition of circulating immune cells, consistent with impaired B-cell differentiation and survival.

Autoimmunity paradox. Despite causing immunodeficiency, C104R carriers paradoxically show elevated autoimmune complications. This reflects a fundamental feature of TACI biology: TACI is not only a survival signal but also a negative regulator of autoreactive B cells. Heterozygous carriers show impaired elimination of autoreactive clones — the dominant-negative mechanism disrupts both the pro-survival and the tolerance-maintaining arms of TACI signalling.

Practical Actions

The actionable implications of C104R focus on immunoglobulin monitoring and infection vigilance. Carriers who develop symptomatic hypogammaglobulinemia (low IgG or IgA) may qualify for immunoglobulin replacement therapy, which is highly effective at preventing recurrent bacterial infections in CVID. Even asymptomatic carriers warrant baseline immunoglobulin quantification, as subclinical IgA or IgG deficiency may go unrecognized until a serious infection occurs.

For heterozygous carriers, the dominant-negative mechanism means the practical risk lies between the normal and homozygous extremes. Many heterozygous C104R carriers remain subclinically affected — their infection burden is elevated but they do not meet formal CVID diagnostic criteria. Regular immunoglobulin monitoring and a low threshold for medical evaluation of recurrent infections are the cornerstones of management.

Interactions

CVID is polygenic in most cases. TACI mutations are neither necessary nor sufficient for CVID — they increase susceptibility, and additional genetic or environmental triggers determine whether frank immunodeficiency develops. Combinations with variants in BAFF (rs9514828, rs1048990), the BAFF receptor TNFRSF13C, or MSH5 at the MHC region have been proposed as modifiers. The GWAS data showing tonsillectomy association (OR 1.59) reflects the penetrance of the variant in an unselected general population — most G allele carriers do not have a formal CVID diagnosis but carry measurable immune disadvantage across their lifetime.